Evidence for paper review

Visual review — "Gut Microbiome and Estrogen" (DOI: 10.6118/jmm.24024)

Strengths (evidence-linked)

• Covers multiple organ-systems evidencing a broad literature search and useful clinical framing Scope of review (Kim et al.)
• Correct emphasis on the estrobolome (microbial β-glucuronidases) — aligns with prior foundational reviews about estrogen–microbiome physiology Baker et al., Maturitas 2017

Key limitations & potential biases

1. Narrative (non-systematic) method: no explicit search strategy, selection criteria, or risk-of-bias assessment are reported, which increases susceptibility to publication/selection bias Methods: narrative review
2. Over-reliance on animal and cross-sectional human data: causal claims are not justified; translational gaps remain (ovariectomized rodents ≠ human menopause) — consistent with critiques in recent osteoporosis/estrogen reviews Osteoporosis–microbiome review
3. Functional inference limited: important mechanistic claims (e.g., changes in β-glucuronidase activity) are often cited from biochemical or predicted functional studies rather than direct metagenomic/metatranscriptomic measurement in humans Functional evidence note
4. Reproducibility and data gaps: the review provides no meta-analytic data, raw datasets, or PRISMA-like transparency; reproducibility score is low in metadata (3/10). This restricts readers from independently verifying synthesis choices.

Where the paper is correct (robust consensus)

• Bidirectional interactions between estrogen and gut microbiota are biologically plausible and supported by biochemical pathways (enterohepatic circulation, microbial deconjugation) and consistent literature Baker et al., Maturitas 2017
• The estrobolome (GUS activity) is a credible mechanistic node influencing free estrogens; multiple studies identify microbial GUS genes across taxa and link them to estrogen reactivation in ex vivo assays (consistent with cited literature).

Where claims need tempering or new data

The review extrapolates from associations (microbiome differences in disease) to suggest therapeutic interventions (probiotics, FMT, estrobolome inhibitors). These suggestions are plausible but currently speculative without large RCTs or causal human mechanistic trials; recent field-level reviews echo this caution Metabolites 2025 review

Concrete, practical recommendations for the authors (and future reviewers)

1. State transparent methods: add PRISMA-like flow, search strategy, inclusion/exclusion criteria, and a table of study-level bias/risk to show how evidence was selected.
2. Distinguish evidence types: explicitly mark claims supported by human longitudinal RCTs vs cross-sectional human studies vs animal models vs ex vivo enzyme assays.
3. Prioritize functional/omic evidence: where possible cite shotgun metagenomics/metatranscriptomics and measured enzymatic activity (β-glucuronidase) rather than 16S inference for function.
4. Be explicit about translational gaps: clearly mark OVX and rodent model limitations and differences between estrous/menstrual biology.

Minimal graphical evidence reproduction

Final critical synthesis (short)

This narrative review usefully organizes the estrogen–microbiome literature and highlights the estrobolome as a mechanistic focus; however, the lack of systematic methods, limited primary human functional evidence, and dependence on animal/cross-sectional data constrain causal claims and translational recommendations. The paper is a strong clinical primer but not a definitive evidence synthesis — next steps require standardized longitudinal human cohorts, shotgun functional metagenomics, and interventional RCTs to test causality.